Novel Schizophrenia Drug Shows ' Favorable Weight Profile ' Novel Schizophrenia Drug Shows ' Favorable Weight Profile '

In topline results from the phase 3 ENLIGHTEN-2 trial, patients with schizophrenia who received olanzapine/samidorphan showed significant less weight gain than those who received olanzapine alone.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Psychiatry News Source Type: news